Cargando…
Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
A number of promising new approaches for both local and systemic control of locally advanced non–small cell lung cancer have been examined in clinical trials, aimed at improving the patient survival. Development of better systemic therapies by adopting newer agents (such as epidermal growth factor r...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144660/ https://www.ncbi.nlm.nih.gov/pubmed/27702837 http://dx.doi.org/10.1093/jjco/hyw131 |
_version_ | 1782473165671235584 |
---|---|
author | Horinouchi, Hidehito |
author_facet | Horinouchi, Hidehito |
author_sort | Horinouchi, Hidehito |
collection | PubMed |
description | A number of promising new approaches for both local and systemic control of locally advanced non–small cell lung cancer have been examined in clinical trials, aimed at improving the patient survival. Development of better systemic therapies by adopting newer agents (such as epidermal growth factor receptor-tyrosine kinase inhibitors and immune checkpoint inhibitors) from advanced non–small cell lung cancer is mandatory. As for radiotherapy, adaptive radiotherapy and proton therapy are under investigation after the RTOG 0617 trial unexpectedly failed to show the efficacy of high-dose radiotherapy for Stage III disease. To date, no Phase III trial has clearly shown the benefit of adding surgery as a part of multimodality therapy for locally advanced non–small cell lung cancer. Such poor progress in the development of effective treatments for Stage III non–small cell lung cancer is considered to be attributable to the existence of heterogeneities in the disease characteristics, including the biological and anatomic characteristics. Constant effort via well-designed and well-conducted clinical trials is needed to decipher the heterogeneity of Stage III non–small cell lung cancer. |
format | Online Article Text |
id | pubmed-5144660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-51446602016-12-09 Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§) Horinouchi, Hidehito Jpn J Clin Oncol Debate A number of promising new approaches for both local and systemic control of locally advanced non–small cell lung cancer have been examined in clinical trials, aimed at improving the patient survival. Development of better systemic therapies by adopting newer agents (such as epidermal growth factor receptor-tyrosine kinase inhibitors and immune checkpoint inhibitors) from advanced non–small cell lung cancer is mandatory. As for radiotherapy, adaptive radiotherapy and proton therapy are under investigation after the RTOG 0617 trial unexpectedly failed to show the efficacy of high-dose radiotherapy for Stage III disease. To date, no Phase III trial has clearly shown the benefit of adding surgery as a part of multimodality therapy for locally advanced non–small cell lung cancer. Such poor progress in the development of effective treatments for Stage III non–small cell lung cancer is considered to be attributable to the existence of heterogeneities in the disease characteristics, including the biological and anatomic characteristics. Constant effort via well-designed and well-conducted clinical trials is needed to decipher the heterogeneity of Stage III non–small cell lung cancer. Oxford University Press 2016-12 2016-12-08 /pmc/articles/PMC5144660/ /pubmed/27702837 http://dx.doi.org/10.1093/jjco/hyw131 Text en © The Author 2015. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Debate Horinouchi, Hidehito Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§) |
title | Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
|
title_full | Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
|
title_fullStr | Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
|
title_full_unstemmed | Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
|
title_short | Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
|
title_sort | role of multimodality therapy in ciiia-n2 non–small cell lung cancer: perspective(§) |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144660/ https://www.ncbi.nlm.nih.gov/pubmed/27702837 http://dx.doi.org/10.1093/jjco/hyw131 |
work_keys_str_mv | AT horinouchihidehito roleofmultimodalitytherapyinciiian2nonsmallcelllungcancerperspective |